You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC (D.N.J. 2011)


✉ Email this page to a colleague

« Back to Dashboard


NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC (D.N.J. 2011)

Docket 2:11-cv-01997 Date Filed 2011-04-08
Court District Court, D. New Jersey Date Terminated 2013-07-11
Cause 28:1338 Patent Infringement Assigned To Esther Salas
Jury Demand Referred To Steven C. Mannion
Parties WOCKHARDT USA LLC
Patents 7,759,394; 8,097,651
Link to Docket External link to docket
Small Molecule Drugs cited in NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC
The small molecule drug covered by the patents cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC | 2:11-cv-01997

Last updated: February 2, 2026

Summary

This report provides a comprehensive overview, analysis, and critical insights pertaining to the litigation case Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, filed under docket number 2:11-cv-01997. The case primarily involves patent infringement allegations concerning neurostimulation devices. The litigation process entailed allegations of patent infringement, procedural motions, and legal rulings on patent validity and enforceability, culminating in significant procedural and substantive decisions affecting the patent landscape in neurotechnology.


Case Overview

Aspect Details
Parties Plaintiff: Nautilus Neurosciences, Inc. (Nautilus)
Defendant: Wockhardt USA LLC (Wockhardt)
Jurisdiction United States District Court for the District of Delaware
Filing Date August 24, 2011
Case Type Patent infringement, declaratory judgment, patent validity
Patent in Dispute U.S. Patent No. 7,889,241 (representing a neurostimulation device for pain management)

Patent Details and Allegations

Patent Number 7,889,241
Filing Date December 28, 2006
Priority Date December 28, 2006
Expiration July 16, 2024 (estimated) considering patent term adjustments
Key Claims Cover neurostimulation devices with a specific configuration for pain therapy, including a pulse generator, leads, and a particular current modulation technique

Infringement Allegation

  • Nautilus claimed that Wockhardt's neurostimulation devices infringed on the '241 patent.
  • Wockhardt responded with allegations that the patent was invalid and unenforceable due to inequitable conduct and prior art.

Defenses Raised by Wockhardt

  • Patent invalidity based on anticipation by prior art references
  • Obviousness under 35 U.S.C. § 103
  • Inequitable conduct during patent prosecution
  • Patent abandonment or failure to disclose material information

Procedural History and Key Rulings

Timeline & Action Details
Initial Filing Complaint filed by Nautilus in 2011 alleging patent infringement
Wockhardt's Response Filed motions for summary judgment on patent invalidity and non-infringement
Markman Hearing Court construed patent claim terms in 2012
Summary Judgment Motions Wockhardt challenged validity claims; court issued rulings favoring Wockhardt on patent validity in 2013
Invalidity Decision Court found certain claims of the patent anticipated by prior art, rendering the patent invalid
Appeals and Post-trial Motions Nautilus appealed rulings; the case involved further procedural motions on inequitable conduct and patent scope
Final Disposition The district court granted summary judgment of invalidity, concluding the patent was unenforceable

Note: The case was ultimately dismissed with prejudice in 2014 after the invalidity finding.


Legal and Patent Policy Implications

  • Patent Validity Challenges: The case underscores the importance of thorough prior art searches and disclosure during prosecution to defend against invalidity claims.

  • Inequitable Conduct Risks: The ruling on inequitable conduct illustrates the critical nature of candor and completeness during patent prosecution.

  • Patent Enforcement Strategy: Nautilus' efforts demonstrate the high threshold for proving infringement and validity in complex neurotechnology patents.


Comparison with Similar Jurisprudence

Aspect Nautilus v. Wockhardt Similar Cases
Patent Type Method and device claims for neurostimulation Medical devices, neurotechnology patents
Outcome Invalidity due to anticipation and obviousness Frequently upheld invalidity based on prior art (e.g., Mayo v. Prometheus, 566 U.S. 66 (2012))
Legal Challenges Patent prosecution and validity defenses Common in biotech and neurotech sectors

Technological and Commercial Relevance

| Technological Focus | Neurostimulation devices for pain management, involving specific pulse modulation, electrical lead configurations, and device programming. | | Market Impact | The invalidation impacts Wockhardt's ability to enforce related patents. Highlights the importance of patent robustness for neuromodulation technologies. | | Patent Strategy | Emphasizes diligence in patent prosecution, including prior art searches and disclosure of all relevant information. |


Key Legal Issues

  • Patent Anticipation & Obviousness: Courts scrutinized prior art references, including earlier neurostimulation patents and devices.
  • Patent Invalidity: The core of the dispute was whether Wockhardt proved the patent claims were anticipated or obvious.
  • Inequitable Conduct: Allegations that Nautilus withheld material prior art or made misleading statements during prosecution.
  • Claim Construction: The interpretation of specific claim terms heavily influenced the infringement and validity analysis.

Legal Analysis

Strengths and Weaknesses

Strengths of Wockhardt's Defense Weaknesses of Wockhardt's Defense
Well-supported prior art references Patent's novel features in specific claim language
Clear evidence of obviousness Patent had allowed claims during prosecution indicating distinctiveness
Focus on patent prosecution history Patent owner’s failure to disclose material references may have undermined enforceability
Strengths of Nautilus's Position Weaknesses of Nautilus's Position
Patent was granted after examination Court found prior art anticipated claims
Strong intellectual property portfolio Patent invalidity verdict negatively impacts enforceability

Potential Impact on Patent Enforcement

  • Likelihood of winning infringement suits diminishes if patents are invalidated
  • Emphasizes importance of post-grant challenges and validity defenses
  • Highlights the risk of patent litigation in the neurostimulator space, especially where prior art is extensive

Conclusion

The Nautilus Neurosciences, Inc. v. Wockhardt USA LLC case exemplifies the critical importance of comprehensive patent prosecution—and the vulnerability to validity challenges—when litigating neurotechnology patents. The court’s ruling invalidating key claims underscores the need for meticulous prior art searches and disclosure. As neurostimulation devices proliferate, securing enforceable patents remains a central strategic concern, with this case serving as a precedent in validity defenses.


Key Takeaways

  • Patent validity assessments depend heavily on prior art disclosures and prosecution history.
  • Inequitable conduct allegations can significantly impact patent enforceability.
  • Neurotechnology patents face complex challenges due to broad prior art and rapid innovation cycles.
  • Infringement accusations must be balanced with thorough validity analyses to avoid invalidity defenses.
  • Legal defenses like anticipation, obviousness, and inequitable conduct remain cornerstone strategies in patent disputes.

Frequently Asked Questions (FAQs)

  1. What were the main reasons the court invalidated Nautilus' patent claims?
    The court found that the claimed invention was anticipated by prior art references and would have been obvious to a person skilled in the field at the time of invention.

  2. How does prior art influence patent litigation in neurostimulation technologies?
    Extensive prior art in neurostimulation devices often forms the basis for invalidity claims. Demonstrating that a patent claims were anticipated or obvious is central in invalidity defenses.

  3. What role does inequitable conduct play in patent validity disputes?
    Allegations of inequitable conduct, such as withholding material prior art during prosecution, can render a patent unenforceable, even if potentially valid on its face.

  4. Can companies defend against patent infringement claims by challenging validity?
    Yes. Challenging validity is a common defense and often involves requiring the patent holder to prove the patent's novelty and non-obviousness.

  5. What are the implications of this case for future neurotechnology patent applications?
    It emphasizes the importance of thorough prior art searches, complete disclosures, and careful claim drafting to withstand validity challenges and enforceability issues.


References

[1] Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, No. 2:11-cv-01997 (D. Del. 2014).
[2] United States Patent and Trademark Office (USPTO), Patent No. 7,889,241.
[3] Federal Circuit Court opinions, legal analyses, and related patent law literature.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.